(c) confirms that where a pharmaceutical product is patented in the territory of the importing country , that country has granted or intends to grant a compulsory licence for import of the product concerned in accordance with Article 31 of the TRIPS Agreement and the provisions of the Decision.
(c) apstiprina, ka gadījumā , ja farmaceitisks produkts ir patentēts importētājvalsts teritorijā, valsts ir izsniegusi vai izsniegs obligāto licenci attiecīgā produkta importam saskaņā ar TRIPS nolīguma 31. punktu un lēmuma noteikumiem.